Welcome to our dedicated page for Enliven Therapeutics SEC filings (Ticker: ELVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enliven Therapeutics, Inc. (Nasdaq: ELVN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Enliven files a range of documents with the U.S. Securities and Exchange Commission (SEC), including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K describing material events.
For Enliven, Form 8-K filings are particularly relevant to investors monitoring clinical-stage and corporate milestones. Recent 8-Ks have covered topics such as quarterly financial results, leadership changes including the appointment of a new President and Chief Executive Officer, the adoption of the 2025 Inducement Equity Incentive Plan, and related compensatory arrangements. Amendments on Form 8-K/A may be used to correct or update previously furnished information, such as earnings press releases.
Periodic reports on Form 10-K and Form 10-Q (referenced in Enliven’s press releases) contain more detailed information on research and development expenses, general and administrative costs, net loss, cash, cash equivalents and marketable securities, as well as risk factors and management’s discussion and analysis. These filings help contextualize the company’s ability to fund the ENABLE Phase 1 trial of ELVN-001 and potential future studies.
On Stock Titan, users can review Enliven’s SEC filings alongside AI-powered summaries that explain key points in accessible language, highlight important sections, and help interpret complex disclosures. Real-time updates from EDGAR allow quick access to new filings, while specialized forms such as Form 4 (when available) can be used to track insider equity transactions. This page is a practical starting point for understanding Enliven’s regulatory history, financial reporting, equity plans and material corporate events related to its precision oncology programs.
Enliven Therapeutics’ chief scientific officer, Joseph P. Lyssikatos, reported an indirect sale of company stock through a family trust. On February 6, 2026, The Lyssikatos Revocable Trust sold 5,000 shares of Enliven common stock at a weighted average price of $29.0438 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024.
After this transaction, the trust, for which Lyssikatos serves as trustee, beneficially owned 740,188 shares of Enliven Therapeutics common stock, reported as indirectly owned.
ELVN insider Andrew Phillips filed a notice to sell 21,844 shares of common stock through Morgan Stanley Smith Barney on or about February 2, 2026, on NASDAQ, with an aggregate market value of $611,719.38.
The shares were acquired the same day via a stock option exercise paid in cash. Phillips also sold 1,520 common shares for $42,564.10 on January 22, 2026. Common shares outstanding were 59,347,317 at the time referenced.
The Lyssikatos Revocable Trust 12/15/2011, for which Enliven Therapeutics’ Chief Scientific Officer Joseph P. Lyssikatos serves as trustee, reported pre‑planned sales of company common stock. On January 20, 2026, the trust sold 5,491 shares at a weighted average price of $26.373 per share and a further 14,509 shares at a weighted average price of $26.8995 per share, each under a Rule 10b5-1 trading plan adopted on November 15, 2024. Following these transactions, the trust held 745,188 shares of Enliven Therapeutics common stock indirectly attributable to the reporting person.
Enliven Therapeutics, Inc. director Richard A. Heyman reported planned sales of company common stock by related entities. On January 20, 2026, the Heyman Daigle Trust, for which he serves as trustee, sold 512 shares at $26.4592 and 718 shares at $26.956 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024. After these transactions, the trust held 23,877 shares beneficially for him. Heyman also reported 123,673 shares held directly and 25,545 shares held indirectly through RAHD Capital LLC, where he is a managing member.
Enliven Therapeutics investor plans to sell 1,230 common shares. The planned sale is to be executed through Jefferies LLC on Nasdaq, with an approximate sale date of 01/20/2026 and an aggregate market value of $32,853.30 for this block. The filing notes that 59,000,000 shares of the issuer’s stock were outstanding.
The seller acquired these 1,230 shares as founder shares from Enliven Therapeutics on 01/25/2020. Over the past three months, Richard Heyman has sold additional Enliven securities in two transactions: 8,015 shares on 01/08/2026 for gross proceeds of $200,655.12 and 4,285 shares on 01/09/2026 for gross proceeds of $107,125.60. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about Enliven’s current or prospective operations.
Enliven Therapeutics, Inc. reported an insider transaction involving its Chief Operating Officer, Anish Patel, through an associated family trust. On January 9, 2026, The Patel / Dong Family Trust, for which Patel serves as trustee, sold 48,057 shares of Enliven common stock at a weighted average price of $27.9842, and an additional 243 shares at $28.50.
The filing states these sales were made under a Rule 10b5-1 trading plan adopted on September 30, 2024, which is a pre-arranged plan for trading the issuer’s equity securities. After these transactions, the trust held 215,011 shares of Enliven common stock, all reported as indirectly owned.
Enliven Therapeutics, Inc. insider activity shows that a trust associated with Chief Scientific Officer Joseph P. Lyssikatos sold a total of 132,500 shares of common stock in early January 2026. The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee, reported sales of 7,500 shares at a weighted average price of $20.1282 on 01/08/2026, followed by 33,802 shares at $24.9238 on the same date. On 01/09/2026, the trust sold 41,198 shares at a weighted average price of $24.9008 and 50,000 shares at $29.1343. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024, and after the final sale, the trust beneficially owned 765,188 shares.
Enliven Therapeutics director Richard A. Heyman reported indirect sales of the company’s common stock through entities associated with him. On January 8, 2026, RAHD Capital LLC, for which he serves as a managing member, sold 1,620 shares at $25.00 per share under a Rule 10b5-1 trading plan adopted on November 15, 2024, and held 25,545 shares of Enliven common stock indirectly afterward.
Also on January 8, 2026, the Richard A. Heyman and Anne E. Daigle Trust sold 8,015 shares at a weighted average price of $25.035, and on January 9, 2026 sold a further 4,285 shares at $25.0001, both under a Rule 10b5-1 plan and held 29,392 shares indirectly afterward. In addition, Heyman is reported as directly beneficially owning 123,673 shares of Enliven common stock.
Enliven Therapeutics director Garland J. Scott reported a new stock option grant on a Form 4. On January 7, 2026, he was awarded a stock option to buy 59,372 shares of Enliven Therapeutics, Inc. common stock at an exercise price of $15.47 per share, expiring on January 7, 2036. The filing states that one‑thirty‑sixth of the shares subject to the option will vest on February 7, 2026 and then monthly thereafter, as long as he continues serving as an outside director on each vesting date. The option is reported as directly owned and was granted at a price of $0 for the derivative itself.
Enliven Therapeutics, Inc. director Garland J. Scott filed an initial ownership report showing holdings of fully vested stock options. As of January 7, 2026, he holds options to purchase 13,072 shares of common stock at an exercise price of $24.12 expiring on September 26, 2034, and options to purchase 13,508 shares at an exercise price of $22.47 expiring on February 6, 2035. The filing characterizes these positions as directly owned, and notes that all shares subject to these options are fully vested and exercisable as of the filing date.